Table 3.
Reasons for selecting individual regimen
| Reason | FOLFOX (n=203) |
CAPOX (n=10) |
5-FU/LV (n=12) |
Capecitabine (n=15) |
UFT/LV (n=6) |
|---|---|---|---|---|---|
| No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | |
| Efficacy | 163 (80.3) | 10 (100) | 2 (16.7) | 10 (66.7) | 2 (33.3) |
| Safety | 39 (19.2) | 2 (20) | 4 (33.3) | 12 (80) | 2 (33.3) |
| Patient characteristics | 61 (30.1) | 4 (40) | 7 (58.3) | 6 (40) | 4 (66.7) |
| Age | 6 (3.0) | 1 (10) | 2 (16.7) | 6 (40) | 4 (66.7) |
| Co-morbidity | 1 (0.5) | 0 | 1 (8.3) | 1 (6.7) | 0 |
| Stage | 60 (29.6) | 4 (40) | 5 (41.7) | 1 (6.7) | 0 |
Data overlapping was allowed.
FOLFOX: leucovorin, 5-fluorouracil, and oxaliplatin; CAPOX: capecitabine and oxaliplatin; 5-FU/LV: 5-fluorouracil with leucovorin; UFT/LV: uracil-tegafur and leucovorin